PMID- 31092051
OWN - NLM
STAT- MEDLINE
DCOM- 20200727
LR  - 20200727
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Linking)
VI  - 19
IP  - 6
DP  - 2019 Jun
TI  - Intravenous immunoglobulins for Alzheimer's disease and mild cognitive impairment 
      due to Alzheimer's disease: A systematic review with meta-analysis.
PG  - 475-480
LID - 10.1080/14737175.2019.1620106 [doi]
AB  - Introduction: Alzheimer's disease (AD) is the most common phenotype of dementia. 
      Mild cognitive impairment (MCI) due to AD is believed as a prodromal stage of AD. 
      Intravenous immunoglobulin (IVIG) is a classical immunotherapy and potentially 
      reduces AD-type pathology by anti-Abeta, anti-tau, anti-inflammatory effects, and 
      non-antibody-mediated effects. Areas covered: The authors aimed to determine the 
      efficacy and safety of IVIG for AD and MCI due to AD patients. The electronic 
      databases including PubMed, EMBASE, CINAHL, Cochrane Library, and China National 
      Knowledge Infrastructure were searched until March 2019. The results were pooled 
      via a random-effects model. There were five eligible studies with 772 randomized 
      patients with AD and MCI due to AD, which compared IVIG with placebo. Expert 
      opinion: No significant differences were found in the scores of mini-mental state 
      examination and Alzheimer's disease assessment scale-cognitive subscale and 
      number of patients with adverse events. IVIG is well tolerated in the patients 
      with AD and MCI due to AD, even in long-term therapy for 18 months. Insufficient 
      evidences support IVIG in the treatment of patients with AD and MCI due to AD to 
      improve cognition or disease modification. Well-designed randomized controlled 
      trials with large sample sizes are required in the future.
FAU - Liu, Jia
AU  - Liu J
AD  - a Department of Neurology , Xuanwu Hospital, Capital Medical University , Beijing 
      , China.
FAU - Wang, Lu-Ning
AU  - Wang LN
AD  - b Department of Geriatric Neurology , Chinese PLA General Hospital , Beijing , 
      China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20190523
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Cognitive Dysfunction/*drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous/*pharmacology
MH  - Immunologic Factors/*pharmacology
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Intravenous immunoglobulins
OT  - meta-analysis
OT  - mild cognitive impairment due to Alzheimer's disease
OT  - systematic review
EDAT- 2019/05/17 06:00
MHDA- 2020/07/28 06:00
CRDT- 2019/05/17 06:00
PHST- 2019/05/17 06:00 [pubmed]
PHST- 2020/07/28 06:00 [medline]
PHST- 2019/05/17 06:00 [entrez]
AID - 10.1080/14737175.2019.1620106 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2019 Jun;19(6):475-480. doi: 10.1080/14737175.2019.1620106. 
      Epub 2019 May 23.